Quarterly report pursuant to Section 13 or 15(d)

Development Award and Deferred Revenue (Details Narrative)

v3.7.0.1
Development Award and Deferred Revenue (Details Narrative)
 1 Months Ended 3 Months Ended
Jan. 31, 2017
USD ($)
Aug. 31, 2016
USD ($)
Apr. 20, 2015
USD ($)
Installments
Nov. 30, 2015
USD ($)
May 31, 2015
USD ($)
Mar. 31, 2017
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Development Award [Line Items]                
Deferred revenue               $ 4,500,000
Revenue           $ 1,293,697 $ 396,598  
Cystic Fibrosis Foundation Therapeutics Inc [Member]                
Development Award [Line Items]                
Amount received upon execution of award agreement $ 1,000,000 $ 1,000,000   $ 1,250,000 $ 1,250,000      
Deferred revenue               $ 500,000
Oral Anti-inflammatory Drug [Member] | Cystic Fibrosis Foundation Therapeutics Inc [Member]                
Development Award [Line Items]                
Amount received upon execution of award agreement     $ 4,500,000          
Oral Anti-inflammatory Drug [Member] | Maximum [Member]                
Development Award [Line Items]                
Development award received     $ 5,000,000          
Anabasum [Member]                
Development Award [Line Items]                
Number of installments | Installments     3          
Payment due period after the first commercial sale     90 days          
Royalty payment, sales target     $ 500,000,000          
Anabasum [Member] | Upon Transfer Sale Or Licensing [Member]                
Development Award [Line Items]                
Royalty payable     15,000,000          
Anabasum [Member] | Maximum [Member] | Upon Commercialization Of The Product [Member]                
Development Award [Line Items]                
Royalty payable     25,000,000          
Anabasum [Member] | Maximum [Member] | Upon Reaching The Sales Target [Member]                
Development Award [Line Items]                
Royalty payable     $ 5,000,000